Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 14/20 | 0.59 |
| ▸ | GALR1 | P47211 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815529 | 0.90 | HSD17B10 (0.49) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2773359 | 0.90 | GALR2 (0.56) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2770894 | 0.87 | GALR2 (0.42) | GALR2GALR1GAAMAPTAPAF1 | |
| SCHEMBL2772274 | 0.87 | MAPT (0.48) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2772459 | 0.87 | GBA1 (0.47) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2772473 | 0.87 | GALR2 (0.48) | GALR2GALR1GAAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL2771922 | 0.86 | GBA1 (0.46) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2770859 | 0.86 | GALR2 (0.42) | GALR2GALR1GAAMAPTAPAF1 | |
| SCHEMBL2773512 | 0.85 | PTGS2 (0.52) | GALR2GALR1GAAMAPTKDM4E | |
| SCHEMBL2772634 | 0.85 | MAPT (0.42) | GALR2GALR1GAAMAPTAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | claimed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | claimed |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | GALR2 4657/4885GALR1 4628/4885GAA 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.